💊 Short-Acting Muscarinic Antagonists (SAMA)

SAMAs are bronchodilators primarily used for the rapid relief of bronchospasm in obstructive airway diseases. They are anticholinergic drugs with a shorter duration of action compared to LAMAs.

SAMAs competitively block the action of acetylcholine at muscarinic receptors, predominantly M3 receptors, in the bronchial smooth muscle. This inhibition prevents bronchoconstriction, leading to rapid bronchodilation. Their short half-life necessitates more frequent dosing.

The main indication for SAMAs in the UK is the relief of acute bronchospasm in chronic obstructive pulmonary disease (COPD) and asthma. They are often used in combination with short-acting beta-agonists (SABAs) for enhanced bronchodilation during acute exacerbations. Ipratropium bromide is the most common example.

Absolute contraindications include hypersensitivity to atropine or its derivatives, or to any excipients. Relative contraindications include narrow-angle glaucoma and prostatic hypertrophy, due to the potential for exacerbation of anticholinergic effects. Caution is also advised in patients with urinary retention.

Common adverse effects are generally mild and anticholinergic in nature, such as dry mouth, cough, and throat irritation. Less common but serious effects can include acute narrow-angle glaucoma if the nebulised solution comes into contact with the eyes, and urinary retention. Tachycardia and palpitations may also occur.

Monitoring primarily involves assessing the patient's symptomatic response to treatment. For acute use, observe for improvement in breathing and reduction in wheeze. For regular use, patients should be asked about the frequency of use and any anticholinergic side effects. No specific blood tests are usually required.

Verify patient allergies, particularly to atropine or similar compounds. Counsel patients on the correct inhaler/nebuliser technique and to avoid getting the nebulised solution in their eyes. Emphasise that SAMAs are for 'as needed' relief or acute exacerbations, not for daily maintenance unless specified.

Ipratropium is the classic SAMA, often used in nebulised form for acute COPD/asthma exacerbations. It provides rapid, but short-lived, bronchodilation. Remember it's an anticholinergic, so expect anticholinergic side effects. Often combined with salbutamol (SABA) in acute settings.

SBA questions frequently test the role of SAMAs in acute exacerbations of COPD or asthma, often in combination with SABAs. Distinguishing their role from LAMAs (acute vs. maintenance) is a common trap. Questions might also focus on their anticholinergic side effects and contraindications.